Work

Real-World Outcomes of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib for First-Line Treatment of Advanced Renal Cell Carcinoma

Year: 2025

Type: article

Study design: Observational Study

Source: Clinical Genitourinary Cancer

DOI: 10.1016/j.clgc.2025.102443

Authors: Daniel M. Geynisman, William S. John, Taavy A. Miller, Parisa Asgarisabet, Angelica Falkenstein, Kristin M. Zimmerman Savill, Xin Yin, Viviana del Tejo, Sarah B. Guttenplan, Lisa Rosenblatt

Institutions: Fox Chase Cancer Center, Cardinal Health (United States), Bristol-Myers Squibb (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Bristol-Myers Squibb

OpenAlex ID: W4414559607

FWCI: 0.653

Cites: 14

Cited by: 1

Related to: 10